Allena Pharmaceuticals
Newton
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $198.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2022)
- Ticker: nasdaq:ALNA
- Website: allenapharma.com
- Phone: +1-617-467-4577
Industries & Categories
Biotechnology, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/allena-pharmaceuticals-136086 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.